A scale measures total body weight, not the cause of a change. A plateau after starting a preparation may prompt a useful clinical question, but it cannot establish that visceral fat is falling while fluid is rising. That explanation needs evidence rather than reassurance.
The tesamorelin prescribing information recognizes fluid retention, including edema and related discomfort, as a possible problem. The warning does not mean every weight fluctuation is fluid or that swelling should be treated as a sign of successful treatment.
Do not turn an adverse effect into a benefit marker
A claim that “the fat loss is hidden by water” can be difficult to disprove if no fat compartment is measured. It may encourage someone to dismiss symptoms while waiting for an assumed benefit. A more rigorous approach separates the two questions: what explains the weight change, and is the intended treatment outcome occurring?
A before-and-after photograph cannot fully resolve that distinction. Neither can a body-fat estimate be accepted uncritically without understanding the device and conditions. Measurements are most useful when they match the clinical objective and are interpreted consistently.
Combination use creates further uncertainty. When another weight-loss medicine or several peptides are involved, the scale trend cannot isolate tesamorelin's contribution. A temporal association is relevant, but it is not a complete causal assessment.
New swelling, joint discomfort or other concerning symptoms should be discussed with the treating clinician. This article does not recommend tolerating symptoms, changing a dose, stopping a prescription or adding a substance to remove fluid.
The balanced conclusion is that fluid retention is a recognized possibility, not an automatic explanation. A clinical review should consider the symptoms and the intended benefit separately. The existence of a plausible side effect cannot be used to certify that a desired fat-loss effect is occurring underneath it.